Toceranib Phosphate NEW
| Price | $41 | $68 | $85 |
| Package | 10mg | 25mg | 50mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: Toceranib Phosphate | CAS No.: 874819-74-6 |
| Purity: 98.56% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | Toceranib Phosphate |
| Description | Toceranib Phosphate (SU11654 phosphate), is a selective inhibitor of the tyrosine kinase activity of several members of the split kinase RTK family, including Flk-1/KDR, PDGFR |
| Animal Research | Dogs scheduled to received toceranib phosphate treatment were divided into 2 groups based on SBP recorded at screening: dogs that were normotensive were assigned to Group 2a and dogs diagnosed with HT were assigned to Group 2b. After baseline evaluation, dogs enrolled in Group 2a received toceranib phosphate at a standard dose as previously published.2 Group 2b dogs received toceranib phosphate as described, but were also treated with standard‐of‐care treatment for HT, including amlodipine besylate (0.2–0.4 mg/kg PO q 24 hours), enalapril maleate (0.5 mg/kg PO q 12 hours), or both, initiated at the discretion of the attending veterinarian. Some dogs were treated with additional medications, including corticosteroids, at the discretion of the oncologist. All dogs were re‐evaluated on Day 14 (±3 days) at which time a UPC and blood pressure measurements were performed[1]. |
| In vivo | Systolic blood pressure was significantly (P = 0.0013) higher in previously normotensive treatment dogs after initiation of treatment with toceranib phosphate (152 mmHg ± 19) compared to baseline (136 mmHg ± 14). 37% of treated dogs developed SBP ≥ 160 mmHg. The prevalence of systemic hypertension (37%) and proteinuria (21%) at baseline in treatment dogs did not differ from that of age-matched healthy controls (15% [P = 0.13] and 0% [P = 0.069], respectively)[1]. |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 2.96 mg/mL (5.99 mM), Sonication is recommended. 10% DMSO+90% Saline : 0.3 mg/mL (0.61 mM), Solution. |
| Keywords | VEGFR | Vascular endothelial growth factor receptor | tyrosine kinase | Toceranib Phosphate | Toceranib | SU-11654 Phosphate | SU11654 Phosphate | SU-11654 | SU11654 | SU 11654 Phosphate | SU 11654 | SCFR | Platelet-derived growth factor receptor | PHA-291639 Phosphate | PHA291639 Phosphate | PHA 291639E | PHA 291639 Phosphate | PDGFR | Inhibitor | inhibit | c-Kit | cKit | CD117 |
| Inhibitors Related | Ribociclib | Kojic acid | Decanoic Acid | Sorafenib | Dasatinib | Ethyl linoleate | Oxyresveratrol | 2-Ketoglutaric acid | P-Tolualdehyde | Methyl cinnamate | Chloramphenicol | Pazopanib |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | EMA Approved Drug Library | Kinase Inhibitor Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Kinase Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1.00 |
VIP2Y
|
S&Y Biochem Co.,Ltd
|
2026-06-14 | |
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-06-11 | ||
|
VIP4Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2025-04-04 | ||
|
Hpets Biotech Company (Chongqing) Co.,ltd
|
2024-02-27 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY